• Explore /
  • Poster
  • / Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.

Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.

Abstract Poster

Authors

null

Noopur S. Raje

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Noopur S. Raje , Xavier P Leleu , Alexander M. Lesokhin , Mohamad Mohty , Ajay K. Nooka , Eric Leip , Umberto Conte , Andrea Viqueira , Salomon Manier

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04649359

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8040)

DOI

10.1200/JCO.2023.41.16_suppl.8040

Abstract #

8040

Poster Bd #

32

Abstract Disclosures

Similar Posters

First Author: Cyrille Touzeau

First Author: Maria-Victoria Mateos

First Author: Sebastian Grosicki

First Author: Malin Hultcrantz